Paul Bresge has been a leader in the cell and gene therapy biotech space since 2010. He is co-founder and CEO at Ray Therapeutics, a clinical-stage optogenetics gene therapy company for blinding diseases. Prior to co-founding Ray Therapeutics, Paul served as CEO at jCyte, a late-stage clinical cell therapy company developing a treatment for retinitis pigmentosa. He was involved with jCyte prior to its inception and concluded a $252M licensing deal with Santen Pharmaceutical in 2020. In addition to his current role as CEO, Paul is on the board of directors of Healios, an iPSC company with programs in ophthalmology and oncology. Paul is passionate about supporting companies with emerging technologies that have great potential to address unmet needs for patients with blinding and other diseases.